---
title: Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
date: '2025-02-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39927615/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20250210170905&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Among adults with active lupus nephritis, obinutuzumab
  plus standard therapy was more efficacious than standard therapy alone in providing
  a complete renal response. (Funded by F. Hoffmann-La Roche; REGENCY ClinicalTrials.gov
  number, ...'
disable_comments: true
---
CONCLUSIONS: Among adults with active lupus nephritis, obinutuzumab plus standard therapy was more efficacious than standard therapy alone in providing a complete renal response. (Funded by F. Hoffmann-La Roche; REGENCY ClinicalTrials.gov number, ...